New growth tonic for Indian pharma industry

Read more

The rotten pill

Read more

MAI revised policy will help CRAMs players to observe double digit growth – Sandipan Mandal

Read more

Teva’s generic EpiPen launch stalls months after approval

Read more

Jubilant Life Sciences posts consolidated revenue of ₹ 2,377 crore in Q3’FY19

Read more

MAI scheme amendments to benefit pharma exporters – Bhavin Mehta

Read more

MAI revision will help SMEs in implementing bar-coding of export consignment – Nipun Jain

Read more

Reimbursement of plant inspection charges will be very useful – SV Veerramani

Read more

It is an exporter-friendly initiative – Satish Wagh

Read more

MAI Scheme: Incentivising exports in a new avatar

Read more